Tag: THER

Leave a Reply

Your email address will not be published. Required fields are marked *

Rybrevant Approved for NSCLC With EGFR Exon 20 Insertion Mutations

Efficacy data revealed 40 percent response rate, median response duration of 11.1 months

More Than Half of Cancer Patients Willing to Enroll in Clinical Trials

Participation rates similar for Black and White patients, treatment and cancer control trials